305 related articles for article (PubMed ID: 21570468)
1. Phytanic acid and pristanic acid, branched-chain fatty acids associated with Refsum disease and other inherited peroxisomal disorders, mediate intracellular Ca2+ signaling through activation of free fatty acid receptor GPR40.
Kruska N; Reiser G
Neurobiol Dis; 2011 Aug; 43(2):465-72. PubMed ID: 21570468
[TBL] [Abstract][Full Text] [Related]
2. The influence of the branched-chain fatty acids pristanic acid and Refsum disease-associated phytanic acid on mitochondrial functions and calcium regulation of hippocampal neurons, astrocytes, and oligodendrocytes.
Rönicke S; Kruska N; Kahlert S; Reiser G
Neurobiol Dis; 2009 Nov; 36(2):401-10. PubMed ID: 19703563
[TBL] [Abstract][Full Text] [Related]
3. The Refsum disease marker phytanic acid, a branched chain fatty acid, affects Ca2+ homeostasis and mitochondria, and reduces cell viability in rat hippocampal astrocytes.
Kahlert S; Schönfeld P; Reiser G
Neurobiol Dis; 2005 Feb; 18(1):110-8. PubMed ID: 15649701
[TBL] [Abstract][Full Text] [Related]
4. Stereochemistry of the peroxisomal branched-chain fatty acid alpha- and beta-oxidation systems in patients suffering from different peroxisomal disorders.
Ferdinandusse S; Rusch H; van Lint AE; Dacremont G; Wanders RJ; Vreken P
J Lipid Res; 2002 Mar; 43(3):438-44. PubMed ID: 11893780
[TBL] [Abstract][Full Text] [Related]
5. Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
Mobley JA; Leav I; Zielie P; Wotkowitz C; Evans J; Lam YW; L'Esperance BS; Jiang Z; Ho SM
Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):775-83. PubMed ID: 12917210
[TBL] [Abstract][Full Text] [Related]
6. Identification and diagnostic value of phytanoyl- and pristanoyl-carnitine in plasma from patients with peroxisomal disorders.
Herzog K; van Lenthe H; Wanders RJA; Vaz FM; Waterham HR; Ferdinandusse S
Mol Genet Metab; 2017 Jul; 121(3):279-282. PubMed ID: 28566232
[TBL] [Abstract][Full Text] [Related]
7. Studies on the oxidation of phytanic acid and pristanic acid in human fibroblasts by acylcarnitine analysis.
Verhoeven NM; Jakobs C; ten Brink HJ; Wanders RJ; Roe CR
J Inherit Metab Dis; 1998 Oct; 21(7):753-60. PubMed ID: 9819705
[TBL] [Abstract][Full Text] [Related]
8. The metabolism of phytanic acid and pristanic acid in man: a review.
Verhoeven NM; Wanders RJ; Poll-The BT; Saudubray JM; Jakobs C
J Inherit Metab Dis; 1998 Oct; 21(7):697-728. PubMed ID: 9819701
[TBL] [Abstract][Full Text] [Related]
9. Phytanic acid and very long chain fatty acids in genetic peroxisomal disorders.
Molzer B; Kainz-Korschinsky M; Sundt-Heller R; Bernheimer H
J Clin Chem Clin Biochem; 1989 May; 27(5):309-14. PubMed ID: 2474624
[TBL] [Abstract][Full Text] [Related]
10. Human metabolism of phytanic acid and pristanic acid.
Verhoeven NM; Jakobs C
Prog Lipid Res; 2001 Nov; 40(6):453-66. PubMed ID: 11591435
[TBL] [Abstract][Full Text] [Related]
11. Localization of the oxidative defect in phytanic acid degradation in patients with Refsum's disease.
Mize CE; Herndon JH; Blass JP; Milne GW; Follansbee C; Laudat P; Steinberg D
J Clin Invest; 1969 Jun; 48(6):1033-40. PubMed ID: 4181594
[TBL] [Abstract][Full Text] [Related]
12. Identification of pristanal dehydrogenase activity in peroxisomes: conclusive evidence that the complete phytanic acid alpha-oxidation pathway is localized in peroxisomes.
Jansen GA; van den Brink DM; Ofman R; Draghici O; Dacremont G; Wanders RJ
Biochem Biophys Res Commun; 2001 May; 283(3):674-9. PubMed ID: 11341778
[TBL] [Abstract][Full Text] [Related]
13. The deficient degradation of synthetic 2- and 3-methyl-branched fatty acids in fibroblasts from patients with peroxisomal disorders.
Van Veldhoven PP; Huang S; Eyssen HJ; Mannaerts GP
J Inherit Metab Dis; 1993; 16(2):381-91. PubMed ID: 7692128
[TBL] [Abstract][Full Text] [Related]
14. In vivo study of phytanic acid alpha-oxidation in classic Refsum's disease and chondrodysplasia punctata.
ten Brink HJ; Schor DS; Kok RM; Stellaard F; Kneer J; Poll-The BT; Saudubray JM; Jakobs C
Pediatr Res; 1992 Nov; 32(5):566-70. PubMed ID: 1282700
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of pristanic acid (2, 6, 10, 14 tetramethylpentadecanoic acid) in the plasma of patients with generalised peroxisomal dysfunction.
Poulos A; Sharp P; Fellenberg AJ; Johnson DW
Eur J Pediatr; 1988 Feb; 147(2):143-7. PubMed ID: 2452737
[TBL] [Abstract][Full Text] [Related]
16. Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha.
Zomer AW; van Der Burg B; Jansen GA; Wanders RJ; Poll-The BT; van Der Saag PT
J Lipid Res; 2000 Nov; 41(11):1801-7. PubMed ID: 11060349
[TBL] [Abstract][Full Text] [Related]
17. Phytanic acid metabolism in health and disease.
Wanders RJ; Komen J; Ferdinandusse S
Biochim Biophys Acta; 2011 Sep; 1811(9):498-507. PubMed ID: 21683154
[TBL] [Abstract][Full Text] [Related]
18. Studies on the degradation of [U-3H]-phytanic acid and [U-3H]-pristanic acid in cultured fibroblasts from children with peroxisomal disorders.
Kase BF; Björkhem I
Scand J Clin Lab Invest; 1996 May; 56(3):211-7. PubMed ID: 8761525
[TBL] [Abstract][Full Text] [Related]
19. Identification of fatty aldehyde dehydrogenase in the breakdown of phytol to phytanic acid.
van den Brink DM; van Miert JN; Dacremont G; Rontani JF; Jansen GA; Wanders RJ
Mol Genet Metab; 2004 May; 82(1):33-7. PubMed ID: 15110319
[TBL] [Abstract][Full Text] [Related]
20. Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
Wierzbicki AS
Biochem Soc Trans; 2007 Nov; 35(Pt 5):881-6. PubMed ID: 17956237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
